Background: Hepatocellular carcinoma is the third leading cause of tumor related mortality and develops mostly in patients with chronic liver disease and liver cirrhosis. Human hepatocyte growth factor (HGF) is produced in various organs of the body and is characterized as a multifunctional factor with vari ous biologic activities. Aim: Our aim was to investigate the predictive factors of recurrence specially the role of HGF in patients with HCC treated with TACE. Patients and Methods: one hundred HCC patients treated by TACE who achieved complete response were included and divided into two groups a ccording to disease free survival (DFS) status at 1 year: the non - early recurrence (NER) group (1) and the early recurrence (ER) group (2). Univariate binary logistic regression analysis for the possible risk factors of recurrence showed that AFP, multinodularity and HGF level were significant. Conclusion: high AFP, multinodularity and high HGF were inter-related possible risk factor s for 1-year recurrence of HCC in patients with initial remission following TACE .
KeywordsHepatocellular CarcinomaHepatocyte Growth FactorPrediction of HCC Recurrence
Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. https://doi.org/10.1002/ijc.25516
Simonetti, R.G., Cammà, C., Fiorello, F., Politi, F., D’Amico, G. and Pagliaro, L. (1991) Hepatocellular Carcinoma. A Worldwide Problem and the Major Risk Factors. Digestive Diseases and Sciences, 36, 962-972. https://doi.org/10.1007/BF01297149
Bruix, J. and Sherman, M. (2011) Management of Hepatocellular Carcinoma: An Update. Hepatology, 53, 1020-1022. https://doi.org/10.1002/hep.24199
Park, W., Chung, Y.H., Kim, J.A., Jin, Y.J., Lee, D., Shim, J.H., Lee, D., Kim, K.M., Lim, Y.S., Lee, H.C., et al. (2013) Recurrences of Hepatocellular Carcinoma Following Complete Remission by Transarterial Chemoembolization or Radiofrequency Therapy: Focused on the Recurrence Patterns. Hepatology Research, 43, 1304-1312. https://doi.org/10.1111/hepr.12083
Kohles, N., Nagel, D., Jüngst, D., Durner, J., Stieber, P. and Holdenrieder, S. (2012) Prognostic Relevance of Oncological Serum Biomarkers in Liver Cancer Patients Undergoing Transarterial Chemoembolization Therapy. Tumor Biology, 33, 33-40. https://doi.org/10.1007/s13277-011-0237-7
Hsu, K.F., Chu, C.H., Chan, D.C., et al. (2012) Superselective Transarterial Chemoembolization vs Hepatic Resection for Resectable Early-Stage Hepatocellular Carcinoma in Patients with Child-Pugh Class a Liver Function. European Journal of Radiology, 81, 466-471. https://doi.org/10.1016/j.ejrad.2010.12.058
Lencioni, R. and Llovet, J.M. (2010) Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Seminars in Liver Disease, 30, 52-60. https://doi.org/10.1055/s-0030-1247132
Ueno, S., Tanabe, G., Nuruki, K., et al. (2002) Prognostic Performance of the New Classification of Primary Liver Cancer of Japan (4th Edition) for Patients with Hepatocellular Carcinoma: A Validation Analysis. Hepatology Research, 24, 395-403. https://doi.org/10.1016/S1386-6346(02)00144-4
Higashio, K., Shima, N., Goto, M., et al. (1990) Identity of a Tumorcytotoxic Factor from Human Fibroblasts and Hepatocytegrowth Factor. Biochemical and Biophysical Research Communications, 170, 397-404. https://doi.org/10.1016/0006-291X(90)91287-3
Tsubouchi, H., Niitani, Y., Hirono, S., et al. (1991) Levels of the Human Hepatocyte Growth Factor in Serum of Patients with Various Liver Diseases Determined by an Enzyme-Linked Immunosorbent Assay. Hepatology, 13, 1-5. https://doi.org/10.1002/hep.1840130102
Nagai, T., Arao, T., Furuta, K., Sakai, K., Kudo, K., Kaneda, H., et al. (2011) Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 10, 169-177. https://doi.org/10.1158/1535-7163.MCT-10-0544
Ferrucci, J. and Mathieu, D. (2004) Advances in Hepatobiliary Radiology. The CV Mosby Company, St. Louis, Vol. 12, 295-305.
Achenbach, T., Seifert, J.K., Pitton, M.B., et al. (2002) Chemoembolization for Primary Liver Cancer. European Journal of Surgical Oncology, 28, 37-41. https://doi.org/10.1053/ejso.2001.1181
Lee, J.K., Chung, Y.H., Song, B.C., Shin, J.W., Choi, W.B., Yang, S.H., et al. (2002) Recurrences of Hepatocellular Carcinoma Following Initial Remission by Transcatheter Arterial Chemoembolization. Journal of Gastroenterology and Hepatology, 17, 52-58. https://doi.org/10.1046/j.1440-1746.2002.02664.x
Matsuda, M., Omata, F., Fuwa, S., Saida, Y., Suzuki, S., Uemura, M., Ishii, N., Iizuka, Y., Fukuda, K. and Fujita, Y. (2013) Prognosis of Patients with Hepatocellular Carcinoma Treated Solely with Transcatheter Arterial Chemoembolization: Risk Factors for One-Year Recurrence and Two-Year Mortality (Preliminary Data). Internal Medicine, 52, 847-853. https://doi.org/10.2169/internalmedicine.52.9356
Okuda, H., Nakanishi, T., Takatsu, K., et al. (2001) Comparison of Clinicopathological Features of Patients with Hepatocellular Carcinoma Seropositive for Alpha-Fetoprotein Alone and Those Seropositive for Des-Gamma-Carboxy Prothrombin Alone. Journal of Gastroenterology and Hepatology, 16, 1290-1296. https://doi.org/10.1046/j.1440-1746.2001.02610.x
Evdokimova, V.N., Liu, Y., Potter, D.M. and Butterfield, L.H. (2007) AFP-Specific CD4+ Helper T-Cell Responses in Healthy Donors and HCC Patients. Journal of Immunotherapy, 30, 425-437. https://doi.org/10.1097/CJI.0b013e31802fd8e2
Shiota, G., Okano, J., Kawasaki, H., Kawamoto, T. and Nakamura, T. (1995) Serum Hepatocyte Growth Factor in Liver Diseases: Clinical Implications. Hepatology, 21, 106-112. https://doi.org/10.1002/hep.1840210119
Yamagamim, H., Moriyama, M., Matsumura, H., Aoki, H., Shimizu, T., Saito, T., et al. (2002) Serum Concentrations of Human Hepatocyte Growth Factor Is a Useful Indicator for Predicting the Occurrence of Hepatocellular Carcinomas in C-Viral Chronic Liver Diseases. Cancer, 95, 824-834. https://doi.org/10.1002/cncr.10732
El Deen, S.H. and El-Haddad, H. (2015) Significance of Hepatocyte Growth Factor Concentrations in Serum of Patients with Liver Cirrhosis and Patients with Hepatocellular Carcinoma. The Egyptian Journal of Internal Medicine, 27, 92-102. https://doi.org/10.4103/1110-7782.165437
Hamed, M.A. and Ali, S.A. (2013) Non-Viral Factors Contributing to Hepatocellular Carcinoma. World Journal of Hepatology, 5, 311-322. https://doi.org/10.4254/wjh.v5.i6.311
Karabulut, S., Tas, F., Akyüz, F., Ormeci, A.C., Serilmez, M., Soydinç, H.O., et al. (2014) Clinical Significance of Serum Hepatocyte Growth Factor (HGF) Levels in Hepatocellular Carcinoma. Tumor Biology, 35, 2327-2333. https://doi.org/10.1007/s13277-013-1308-8
Matsumoto, K. and Nakamura, T. (2006) Hepatocyte Growth Factor and the Met System as a Mediator of Tumor-Stromal Interactions. International Journal of Cancer, 119, 477-483. https://doi.org/10.1002/ijc.21808
Van Belle, E., Witzenbichler, B., Chen, D., Silver, M., Chang, L., Schwall, R. and Isner, J.M. (1998) Potentiated Angiogenic Effect of Scatter Factor/Hepatocyte Growth Factor via Induction of Vascular Endothelial Growth Factor: The Case for Paracrine Amplification of Angiogenesis. Circulation, 97, 381-390. https://doi.org/10.1161/01.CIR.97.4.381
Birchmeier, C. and Gherardi, E. (1998) Developmental Roles of HGF/SF and Its Receptor, the c-Met Tyrosine Kinase. Trends in Cell Biology, 8, 404-410. https://doi.org/10.1016/S0962-8924(98)01359-2